All Wales Medicines Strategy Group

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan

Final Appraisal Recommendation

Advice No: 1313 – May 2013

Perampanel (Fycompa®▼) 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg film-coated tablets

Submission by Eisai Ltd

Recommendation of AWMSG

Perampanel (Fycompa®▼) is recommended as an option for restricted use within NHS Wales. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.

Perampanel (Fycompa®▼) should be restricted to treatment of patients whose seizures are still uncontrolled with first adjunctive therapy, within its licensed indication as adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.

Perampanel (Fycompa®▼) is not recommended for use within NHS Wales outside of this subpopulation.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1219), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	Eisai Ltd
Date of first issue	May 2013
Last reviewed	August 2016